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Open access under CC BYA randomized, controlled, open-label, parallel-group, single-center study to determine biomarkers of
exposure to 12 selected harmful and potentially harmful constituents (HPHC) in cigarette smoke, excre-
tion of mutagenic material in urine, and serum Clara cell 16-kDa protein (CC16) in 102 male and female
Japanese subjects who smoked Marlboro Ultra Lights Menthol cigarettes (M4JM; 4 mg tar and 0.3 mg nic-
otine) at baseline. Subjects were randomized to continue smoking M4JM, or switch to smoking either the
Electrically Heated Cigarette Smoking System menthol cigarette (EHCSS-K6M; 5 mg tar and 0.3 mg nico-
tine) or the Lark One menthol cigarette (Lark1M; 1 mg tar and 0.1 mg nicotine), or to no-smoking. The
mean decreases from baseline to Day 5/6 were statistically signiﬁcant (p 6 0.05) for exposure to 10 of
12 cigarette smoke HPHC including the primary endpoint (carbon monoxide) and urinary excretion of
mutagenic material in the EHCSS-K6M group (12.3% to 83.4%). Smaller, but statistically signiﬁcant
reductions (p 6 0.05) occurred in the Lark1M group (3.3% to 35.2%), with the exception of urinary
mutagens. The largest mean reductions (all p 6 0.05) in exposure to cigarette smoke HPHC and excretion
of mutagenic material occurred in the no-smoking group (1.4% to 93.6%). Serum CC16, an indicator of
lung epithelial injury, was not signiﬁcantly different between groups.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction cigarettes in laboratory-based test systems (Werley et al., 2008;There is overwhelming medical and scientiﬁc consensus that
cigarette smoking causes lung cancer, heart disease, emphysema,
and other serious diseases in smokers (US Department of Health
and Human Services, 2010; Ministry of Health, Labour andWelfare,
Japan, 2008). In the US the Family Smoking Prevention and Tobacco
Control Act (FSPTCA) (Family Smoking Prevention and Tobacco
Control Act, 2009) has empowered the Food and Drug Administra-
tion (FDA) to evaluate and regulate modiﬁed risk tobacco products
(MRTPs) (Deyton et al., 2010). The FDA, in consultation with the
Institute of Medicine (IOM), has also been charged to issue guid-
ance and regulations on the scientiﬁc evidence required for the
assessment and ongoing review of MRTPs (Food and Drug Admin-
istration, 2012; Institute of Medicine, 2012).
Use of the Electrically Heated Cigarette Smoking System
(EHCSS) series-K heater and the menthol EHCSS series-K cigarette
results in reduced levels of a wide range of toxicologically impor-
tant cigarette smoke HPHC and signiﬁcantly lowers the biological
activity of mainstream smoke compared to conventional lit-end. Tricker).
-NC-ND license.Zenzen et al., 2012). Electrical heating of the tobacco reduces pyro-
lysis, and produces smoke that contains lower amounts of most
cigarette smoke HPHC. The current third-generation EHCSS puff-
activated electrical heater can be used to smoke either series-K
non-menthol or menthol cigarettes. The series-K menthol cigarette
has a mainstream smoke delivery of 5 mg tar and 0.3 mg nicotine
when tested according to International Organization for Standard-
ization (ISO) methods. The EHCSS heater cannot be used to smoke
conventional lit-end cigarettes.
The current communication, the fourth in a series of ﬁve clinical
evaluations describing data from clinical investigations performed
under both controlled and real-life smoking conditions (Martin
Leroy et al., 2012; Tricker et al., 2012a,b,c), reports a randomized,
controlled, open-label, parallel-group, single-center study. Subjects
smoking theMarlboro Ultra Lights Menthol cigarette (M4JM) at base-
line were randomized to continue smoking the M4JM cigarette, or
switch to smoking the EHCSS-K6 menthol cigarette (EHCSS-K6M),
or switch to the Lark One menthol cigarette (Lark1M), or to switch
to no-smoking, for a duration of 6 days. The tested cigarettes were
commercially available on the Japanese market. The study was
designed to examine changes in selected tobacco-speciﬁc and -
related biomarkers of exposure to HPHC present in the gas–vapor
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crotonaldehyde, and menthol) and the particulate phase (2-naph-
thylamine, 4-aminobiphenyl, 4-methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone (NNK), acrylamide, nicotine, pyrene, and
o-toluidine) of mainstream cigarette smoke, as well as excretion
of mutagenic material in urine. The use of suitable biomarkers of
exposure to these compounds offers one potential method to
assess whether differences in exposure to cigarette smoke HPHC
has occurred in smokers switching from one cigarette to another
(Shields, 2002; Hatsukami et al., 2005). In addition, serum Clara
cell 16 kDA protein was determined as an investigational
biomarker of lung epithelial injury (Robin et al., 2002).
The primary objective of the study was to compare exposure to
CO, determined as the carboxyhemoglobin concentration in blood
at 17:00 (COHb17:00), between the study groups on Day 5/6 (aver-
age of values on Day 5 and Day 6). Exposure to CO was selected as
the primary objective based on the reduction of CO in mainstream
smoke compared to conventional cigarettes (Werley et al., 2008;
Zenzen et al., 2012) and the previous observation that COHb is
reduced in smokers after switching to the EHCSS (Frost-Pineda
et al., 2008a,b).2. Materials and methods
2.1. Subjects
Adult male and female Japanese smokers (21–50 years of age)
with acceptable health conditions who smoked for at least a year,
and had smoked exclusively 10–30 menthol cigarettes (3–6 mg tar
yield) per day for at least 2 months were recruited. All subjects
provided a signed written informed consent prior to screening
and other study procedures. Subjects were compensated for study
participation and were free to withdraw from the study at any
time. Screening was performed 2 weeks prior to in-clinic study
conﬁnement and included medical history, physical examination,
vital signs, electrocardiogram (ECG), pulmonary function tests,
clinical laboratory tests, urine pregnancy test, blood COHb, and
the Fagerström Test for Nicotine Dependence (FTND) (Heatherton
et al., 1991). Women of childbearing potential who used a reliable
method of contraception were considered as eligible for study
inclusion; pregnant or lactating women were excluded. Other
exclusion criteria included clinically signiﬁcant disease, alcohol
or drug abuse, <1.5% COHb (suggestive of being a non-smoker),
<12.5 g/dl hemoglobin or <38% hematocrit, body mass index
(BMI) 617.6 and P26.4, a positive test for human immunodeﬁ-
ciency virus (HIV) or hepatitis, and use of a nicotine-containing
product other than cigarettes within 3 months prior to screening.
The use of any medication with the exceptions of occasional use
of paracetamol (up to 1 g/day) to treat headache and hormonal
contraceptives for female subjects during the week before admis-
sion to the clinic was prohibited.2.2. Cigarette products
Conventional cigarette (CC) brands were selected to include a
leading market share cigarette of similar ISO tar and nicotine yields
to the EHCSS- K6M and a representative CC with a low ISO tar and
nicotine yield. The cigarettes also had a similar tobacco blend to
that used in the EHCSS test cigarettes. Study cigarettes were ana-
lyzed for tar and nicotine according to ISO methods. Study ciga-
rettes were conditioned according to ISO standard 3402
(International Organization for Standardization, 1991). Conven-
tional cigarettes were smoked on a smoking machine according
to ISO standard 3308 (International Organization for Standardiza-
tion, 2000a). Tar and, nicotine were determined according to ISOstandards 4387 and 10315, respectively (International Organiza-
tion for Standardization, 2000b,c). These methods are essentially
similar to methods used by the Tobacco Institute of Japan for dec-
laration of tar and nicotine levels on cigarette packaging. Main-
stream smoke from EHCSS cigarettes was generated on a
modiﬁed smoking machine with a carousel adapted to use the
EHCSS series-K lighter. The EHCSS smoke generation conformed
with ISO standard 3308; some slight technical deviations were re-
quired. The ISO yields as declared on the cigarette packaging were
as follows: Marlboro Ultra Lights Menthol (M4JM; 4 mg tar and
0.3 mg nicotine), Lark One Menthol (Lark1M; 1 mg tar and 0.1 mg
nicotine), and EHCSS series-K menthol (EHCSS-K6M; 5 mg tar,
0.3 mg nicotine). All cigarettes used in the study contained
menthol.
2.3. Study design and conduct
The recruited subjects (N = 102; 62 males and 40 females) com-
pleted a 7-day diary prior to in-clinic admission on Day 3 (Fig. 1).
The median daily cigarette consumption according to the 7-day
diary was used to determine the maximum number of cigarettes
that the subject could smoke per day during the study (median
plus 2 cigarettes, with a maximum of either 19 or 30 cigarettes
per day (CPD) depending on the stratiﬁcation group). On Day 3,
the eligibility for study inclusion was re-conﬁrmed. The subjects
were conﬁned to the clinic from Day 3 to Day 7 under medical
supervision. Assessments included COHb and vital signs (15:00),
and a physical examination. On Day 2, vital signs and a 12-lead
ECG were measured (07:00) and blood samples drawn for clinical
laboratory tests. On Day 1 and Day 0 (baseline days), assessments
included determination of biomarkers of exposure in a 24-h urine
sample (combined urine voids starting at 07:00), vital signs
(07:00), serum CC16 (07:00 on Day 0), COHb (COHb07:00 and
COHb17:00; 07:00 and 17:00), and plasma cotinine (COT-P17:00;
17:00). On Day 0, one hundred subjects (61 males and 39 females)
were randomized into 1 of 4 parallel groups (EHCSS-K6M, M4JM,
Lark1M, and no-smoking; N = 28 per smoking group, and N = 16
in the no-smoking group) using a stratiﬁcation based on gender
and median daily cigarette consumption (10–19 and 20–30 CPD).
On randomization, subjects continuing to smoke conventional cig-
arettes (M4JM or Lark1M) were ‘blind’ to the identity of the test cig-
arettes. Non-randomized subjects were released from the study
center after completing scheduled assessments. Subjects with-
drawing from the study or those removed by the Investigator after
baseline were not replaced. From Day 1 through Day 6, subjects
participated in their assigned study groups. Assessments included
determination of biomarkers of exposure in 24-h urine samples
(starting at 07:00 on Days 1, 3, 5, and 6), vital signs (07:00), Clara
cell 16-kDa protein (07:00, Day 6 only), COHb07:00, COHb17:00, and
COT-P17:00. On Day 7 (end-of-study), vital signs, 12-lead ECG, clin-
ical laboratory tests, and a physical examination were performed at
07:00 prior to release of subjects from the study center.
On Day 3 through Day 0 subjects were only permitted to
smoke the M4JM cigarette, on Day 1 through Day 6 subjects
smoked according to their randomized study group. M4JM and
Lark1M cigarettes were lit using a blue ﬂame gas lighter. EHCSS-
K6M cigarettes were smoked using the EHCSS heater (Werley
et al., 2008). To ensure study integrity, all M4JM and Lark1M ciga-
rette butts and smoked EHCSS-K6M cigarettes were collected.
Smoking was permitted only at designated smoking times from
07:30 to 23:00 and subjects were not encouraged to smoke at
any time during the study. The subjects received a dietician-de-
signed low-mutagen diet (Smith et al., 1996) containing foodstuffs
known not to contain menthol. The menus were identical on Days
1, 2 and 5 (days preceding determination of urinary mutagenic-
ity), and on Days 0, 3 and 6 (days on which urinary mutagenicity
Fig. 1. Schedule of study events. Footnote: On Day 1/0 (baseline) all subjects smoked the M4JM cigarette prior to randomization into the four study groups. All cigarettes
described in Table 2.
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tion of caffeinated beverages was not permitted. A menthol-free
toothpaste was provided by the clinic and used by the subjects.
The study was conducted at the Osaka Clinical Research Organi-
sation for Medicine (OCROM) Clinic, 4-12-11 Kasuga, Suita-shi,
Osaka 565-0853, Japan, and was conducted in compliance with
the ethical principles that have their origin in the Declaration of
Helsinki and that are consistent with Good Clinical Practice
(1964, and regularly amended; 1996) and Good Clinical Practice
Guidelines issued by the Japanese Ministry of Health, Labour and
Welfare (2004). The study was approved by the OCROM Clinic
Institutional Review Board, Osaka, Japan.
2.4. Bioanalytical methodology
Urine voided in a 24-h period on studyDays1, 1, 3, 5, and 6was
stored refrigerated at 2–8 C on the day of urine collection, total ur-
ine volumemeasured, and aliquots stored frozen at20 C pending
biomarker analysis (Table 1). Both tobacco-speciﬁc and tobacco-Table 1
Summary of smoke constituent biomarkers of exposure, and bioanalytical methods.
Smoke constituent Biomarker
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA)
2-Naphthylamine 2-Naphthylamine (2-NA)
4-Aminobiphenyl 4-Aminobiphenyl (4-ABP)
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA)
Acrylamide Acrylamide mercapturic acid (AAMA)
Glycidamide mercapturic acid (GAMA)
Benzene S-Phenyl mercapturic acid (S-PMA)
Carbon monoxide Carboxyhemoglobin (COHb)
Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA)
Nicotine Cotinine (COT-P)
Nicotine equivalents (NEq)c
NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)d
Pyrene Total 1-hydroxypyrene (1-OHP)e
o-Toluidine o-Toluidine (o-TOL)
Mutagens Salmonella mutagenicity (YG1024 with S9)
a LC–MS/MS, liquid chromatography-tandem mass spectrometry.
b NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine,
d Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the
conjugate.
e Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyr
f NA, not applicable.related biomarkers of exposure to HPHC were determined (Hecht,
2003; Lindner et al., 2011; Schorp et al., 2012): (i) tobacco-speciﬁc
biomarkers of exposure were determined for nicotine (Benowitz
et al., 1994) andNNK (Carmella et al., 2003), and (ii) tobacco-related
biomarkers of exposure were selected for 1,3-butadiene (van Sittert
et al., 2000), 2-naphthylamine (Riedel et al., 2006), 4-aminobiphenyl
(Riedel et al., 2006), acrolein (Mascher et al., 2001), acrylamide (Ur-
ban et al., 2006), benzene (Medeiros et al., 1997), crotonaldehyde
(Scherer et al., 2007), pyrene (Stricklandet al., 1996), and o-toluidine
(Riedel et al., 2006). Biomarkers of exposure were determined by li-
quid chromatography–tandem mass spectrometry (LC–MS/MS)
usingmethods validated according to FoodandDrugAdministration
criteria (Food and Drug Administration, 2001). Some of the instru-
mentation used (Table 1) differs to that reported in the original
methods. Excretion of mutagenic material towards Salmonella
typhimurium YG1024 on Days 0, 3, and 6 was determined using
the Ames plate incorporation assay (Einistö et al., 1990). Blood sam-
pleswere drawn in sodiumheparin vacutainer tubes for determina-
tion of COHb and measured on the day of collection byMatrix Analytical methoda Lower limit of quantiﬁcation
Urine LC–MS/MS 100 pg/ml
Urine LC–MS/MS 5.0 pg/ml
Urine LC–MS/MS 5.0 pg/ml
Urine LC–MS/MS 35 ng/ml
Urine LC–MS/MS 2.5 ng/ml
Urine LC–MS/MS 1.5 ng/ml
Urine LC–MS/MS 20 pg/ml
Blood Spectrophotometry 0.3% saturation
Urine LC–MS/MS 92 pg/ml
Plasma LC–MS/MS 10 ng/ml
Urine LC–MS/MS NAf
Urine LC–MS/MS 5.0 pg/ml
Urine LC–MS/MS 10 pg/ml
Urine LC–MS/MS 25 pg/ml
Urine Ames plate incorporation assay NA
and trans-30-hydroxycotinine plus their respective glucuronide conjugates.
molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide
ene and its glucuronide and sulfate conjugates.
A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S64–S73 S67spectrophotometry (Pojer et al., 1984). Plasmawas stored at20 C
prior to analysis of COT-P by LC–MS/MS (Benowitz, 1988). Serum
Clara cell 16-kDa protein (CC16) was determined by ELISA (BioVen-
dor GmbH, Germany).
All laboratory analyses were performed in a blinded manner
without knowledge of the study group assignment.
2.5. Data analysis
For data summary and statistical analysis, biomarker values be-
low the lower limit of qualiﬁcation (LLOQ) were set to LLOQ/2.
Exposure to nicotine was analyzed based on nicotine equivalents
(NEq) excretion, calculated as the molar sum of the concentrations
of nicotine and the ﬁve major nicotine metabolites (nicotine-glu-
curonide, free cotinine, cotinine-glucuronide, free trans-30-
hydroxycotinine, and trans-30-hydroxycotinine-glucuronide) in ur-
ine. Urine samples showing signs of cytotoxicity and/or precipitate
were excluded from the mutagenicity analysis.
Descriptive statistics were derived for each biomarker by study
group and day. Baseline values were calculated as the average of
values on Day 1 and Day 0 (Day 1/0). Baseline comparability
of different study groups was examined using the non-parametric
Kruskal–Wallis test. Changes in biomarker values from baseline to
the average of values on Day 5 and Day 6 (Day 5/6) within each
study group were analyzed by the paired sample t-test (two-sided,
a = 0.05).
Differences at Day 5/6 between M4JM and EHCSS-K6M, and be-
tween Lark1M and EHCSS-K6M, were analyzed by analysis of
covariance (ANCOVA) with factors study group, gender, and daily
cigarette consumption with the absolute value at baseline as
covariate. Interaction terms for study group  gender and study
group  daily cigarette consumption were included into the model
if signiﬁcant interactions (at the a = 0.1 level) were evident. If the
global test showed a signiﬁcant difference between study groups
(at the a = 0.05 level), pair-wise comparisons of EHCSS-K6M and
M4JM and Lark1M, respectively, were performed according to Dun-
nett (one-sided with a Bonferoni-corrected signiﬁcance level of
a = 0.025).
Changes in urinary mutagenicity were analyzed using square
root-transformed data since the data was not normally distributed.
Descriptive statistics were also derived by study group for COHb
concentrations adjusted for the number of cigarettes smoked be-
tween 07:00 and 17:00 (COHbNcig10h), and the molar sum of the
concentrations of nicotine and the ﬁve major nicotine metabolites
(nicotine-glucuronide, free cotinine, cotinine-glucuronide, free
trans-30-hydroxycotinine, and trans-30-hydroxycotinine-glucuro-
nide) in urine was calculated as nicotine equivalents (NEq). NEq
was adjusted by the individual number of cigarettes smoked per
day (NEq17:00/Ncig), and urinary biomarkers of exposure adjusted
for creatinine excretion.
All statistical analyses were of an exploratory nature. Therefore,
apart from adjustment for the pair-wise comparisons for each
EHCSS product with the two conventional cigarettes at biomarker
levels, no further adjustment for multiplicity was performed.
Statistical analyses were performed using SAS Version 9.1.3.
Unless otherwise stated, analyses are reported for the intent-to-
treat population (ITT) which included subjects who had a valid
assessment of the primary biomarker variables at baseline (Day
1 or 0) and at least one post-baseline assessment (subjects in
the smoking groups must have smoked at least one study
cigarette).
2.6. Determination of sample size
It was assumed that Lark1M smokers would have a comparable
concentration of COHb at 17:00 (COHb17:00) to that seen in a pre-vious study in which subjects who smoked the Lark1 non-menthol
cigarette for 8 days had an average concentration of 3.58 ± 1.35%
COHb17:00 calculated from data obtained on study Days 5 and 6
(Tricker et al., 2012c), while the COHb17:00 concentration in the
EHCSS-K3M group was at least 40% lower. For a two-sample t-test
of a mean difference (pairwise comparison of Lark1M with EHCSS-
K6M) with a normal one-sided signiﬁcance level of a = 0.025 and
assuming a common standard deviation of r = 1.6, a sample size
of 27 subjects per group was required to obtain a test power of
at least 90% (1  b = 0.9) to detect a 40% difference in mean
COHb17:00 concentrations between the Lark1M group (3.6%) and
the EHCSS-K6M group (2.16%). A size of 28 subjects in each smok-
ing group was retained in the study for practical reasons. A no-
smoking group was included to show the maximal reduction in
COHb17:00 on smoking cessation. A size of 16 subjects in the no-
smoking group was chosen based on practical reasons.2.7. Adverse events, medical history, and concomitant medication
Adverse events (AEs) and medical history were coded using the
Medical Dictionary for Regulatory Activities (MedDRA Version
9.0). Medication was coded according to the World Health Organi-
zation (WHO) Drug Reference List (Version 1.03).3. Results
3.1. Demographic and other baseline characteristics
The ITT population consisted of 100 subjects (61 males and 39
females). Demographic characteristics by study group are summa-
rized in Table 2. All subjects were of Japanese origin. There were
about twice as many men as women in each study group. The indi-
vidual study groups were balanced with respect to gender and
smoking category (10–19 and 20–30 CPD) ratios. The mean subject
age was 23.9 ± 2.8 years (range: 21–32 years) and mean body mass
index (BMI) was 20.6 ± 2.2 kg/m2 (range: 17.6–26.0 kg/m2). There
were no signiﬁcant differences between males and females with
respect to age, BMI, duration of smoking, average daily cigarette
consumption, and demographic variables in the different study
groups. Most subjects had a smoking history of less than 10 years
(N = 92, 92%) and only 8 subjects (8%) smoked for 10 or more years.
There was no difference in the FTND score between male (mean
score: 3.9 ± 1.7) and female (mean score: 3.9 ± 1.6) subjects. FTND
scores were lower for smokers of 10–19 CPD (mean score:
3.1 ± 1.5) compared to smokers of 20–30 CPD (mean score:
4.6 ± 1.4).
Clinical and laboratory assessments at baseline did not reveal
any clinically signiﬁcant abnormal values in the randomized sub-
jects. After randomization, 99 subjects (60 males and 39 females)
completed the study; one male subject withdrew for personal
reasons.3.2. Cigarette consumption
The mean number of CPD on Day 0 (baseline) was similar
among the four study groups (Table 3). On Day 1, the ﬁrst day
when subjects smoked their respective randomized study ciga-
rette, the mean number of cigarettes smoked was slightly in-
creased in the Lark1M group and slightly decreased in the M4JM
group. The mean number of cigarettes smoked in the EHCSS-K6M
group was unchanged. On Day 6, the average cigarette consump-
tion was slightly higher in the EHCSS-K6M and Lark1M groups com-
pared to baseline, and similar to baseline in the M4JM group.
Table 2
Demographic summary by study group.
Variable and statistics Study groupa
M4JM EHCSS-K6M Lark1M No-smoking
Number (N) 28 28 28 16
Age (mean ± SD) 23.9 ± 2.9 23.6 ± 2.1 24.1 ± 3.3 24.0 ± 3.1
Gender (N, % of total)
Female 13 (46.4%) 11 (39.3%) 10 (35.7%) 5 (31.2%)
Male 15 (53.6%) 17 (60.7%) 18 (64.3%) 11 (68.8%)
BMIb (kg/m2, mean ± SD) 21.16 ± 2.45 20.18 ± 2.20 20.23 ± 1.96 20.78 ± 2.34
Duration of smoking (N years, % of total)
3 years or less 9 (32.1%) 9 (32.1%) 10 (35.7%) 7 (43.8%)
4–9 years 18 (64.3%) 17 (60.7%) 16 (57.1%) 6 (37.5%)
10–15 years 1 (3.6%) 2 (7.1%) 2 (7.1%) 3 (18.8%)
16 years or more 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fagerström Scorec (mean ± SD) 3.9 (1.4) 3.8 (1.6) 3.9 (1.9) 4.0 (1.7)
a Groups abbreviated as: EHCSS-K6M, EHCSS series-K heater and EHCSS-K6 menthol cigarette (5 mg tar and 0.3 mg nicotine); M4JM,Marlboro Ultra Lights Menthol cigarette
(4 mg tar and 0.3 mg nicotine); Lark1M, Lark One menthol cigarette (1 mg tar and 0.1 mg nicotine); and No-smoking, smoking cessation group.
b BMI, body mass index.
c The Fagerström Score was calculated as published (Heatherton et al., 1991).
Table 3
Daily cigarette consumption by group and study day.
Study daya Study Groupb
M4JM EHCSS-K6M Lark1M No-smoking
Day 2 17.9 ± 4.0 17.1 ± 3.6 18.2 ± 4.0 16.8 ± 4.0
Day 1 17.5 ± 3.7 17.1 ± 4.1 17.1 ± 4.5 16.2 ± 4.0
Day 0 (Baseline) 17.4 ± 4.0 17.0 ± 4.4 17.0 ± 5.0 16.9 ± 4.0
Day 1 17.1 ± 4.0 17.0 ± 4.3 17.5 ± 4.7 0
Day 2 16.9 ± 3.6 17.4 ± 4.8 17.6 ± 4.3 0
Day 3 16.9 ± 4.1 17.3 ± 5.1 17.6 ± 4.7 0
Day 4 17.2 ± 4.2 17.0 ± 4.9 17.5 ± 4.6 0
Day 5 17.2 ± 4.1 17.5 ± 4.8 17.5 ± 4.8 0
Day 6 17.3 ± 4.1 17.6 ± 5.1 17.6 ± 4.5 0
a On Day 1/0 (baseline) all groups smoked the M4JM cigarette. On Day 1 through
Day 6 groups smoked their randomized study cigarette or stopped smoking.
b Groups abbreviated as: EHCSS-K6M, EHCSS series-K heater and EHCSS-K6
menthol cigarette (5 mg tar and 0.3 mg nicotine); M4JM, Marlboro Ultra Lights
Menthol cigarette (4 mg tar and 0.3 mg nicotine); Lark1M, Lark One menthol ciga-
rette (1 mg tar and 0.1 mg nicotine); and No-smoking, smoking cessation group.
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There were no statistically signiﬁcant differences in COHb17:00,
the primary study objective, and other measures of exposure to
CO between the four study groups at baseline (Table 4). Statisti-
cally signiﬁcant differences in the four groups were not observed
for any of the other biomarkers of exposure or excretion of muta-
genic material in 24-h urine at baseline.
All assessments of CO exposure were signiﬁcantly decreased
(p < 0.001) in the EHCSS-K6M group. Concentrations of COHb17:00,
the primary endpoint, showed large and statistically signiﬁcant
reductions in the EHCSS-K6M, Lark1M, and no-smoking groups
(all p < 0.001), and a slight increase in the M4JM group at Day 5/
6, compared to baseline (Fig. 2). Similarly, the COHb concentration
adjusted for the number of cigarettes smoked between 07:00 and
17:00 (COHbNcig10h) was signiﬁcantly decreased in the EHCSS-
K6M and Lark1M groups (p < 0.001 and p < 0.01, respectively) at
Day 5/6, compared to baseline. A signiﬁcant increase (p < 0.01)
was evident in the M4JM group. The change in daytime COHb con-
centrations from 07:00 to 17:00 (DCOHb17:00-07:00) showed large
and signiﬁcant decreases in the EHCSS-K6M and no-smoking
groups (both p < 0.001), and no signiﬁcant changes in the M4JM
and Lark1M groups at Day 5/6, compared to baseline. When ad-
justed for the number of cigarettes smoked, DCOHbNcig10h concen-
trations showed a signiﬁcant decrease in the EHCSS-K6M group(p < 0.001), a smaller decrease in the M4JM group (p < 0.05), and
no signiﬁcant change in the Lark1M group at Day 5/6, compared
to baseline.
The majority of the biomarkers of exposure to cigarette smoke
HPHC (1,3-butadiene, 4-aminobiphenyl, acrolein, benzene, croton-
aldehyde, nicotine, NNK, pyrene, and o-toluidine) and excretion of
mutagenic material in urine were statistically signiﬁcantly reduced
in the EHCSS-K6M group at Day 5/6, compared to baseline (Table 4).
Minor reductions were observed in exposure to 2-naphthylamine
and acrylamide in the EHCSS-K6M group. Exposure to 1,3-butadi-
ene, 4-aminobiphenyl, acrolein, acrylamide, benzene, crotonalde-
hyde, nicotine (determined as COT-P17:00 and NEq), NNK, and o-
toluidine, as well as excretion of mutagenic material in urine were
similar, while exposure to pyrene was signiﬁcantly reduced
(p < 0.01) in the M4JM group at Day 5/6, compared to baseline.
All biomarkers of exposure were reduced in the Lark1M group:
The reduction for exposure to acrolein, nicotine (determined as
both COT-P17:00 and NEq), acrolein, NNK, pyrene, and o-toluidine
were all signiﬁcant (p < 0.001). Less signiﬁcant reductions
(p < 0.01) occurred for 1,3-butadiene, 4-aminobiphenyl, acrylam-
ide, benzene, and crotonaldehyde in the Lark1M group. Exposure
to 2-naphthylamine and excretion of mutagenic material in urine
was also decreased. With the exception of 2-naphthylamine, the
largest reductions in biomarkers of exposure to cigarette smoke
HPHC and excretion of mutagenic material in urine were observed
in the no-smoking group (all signiﬁcant at the p 6 0.01 level) at
Day 5/6, compared to baseline. The urinary biomarker observations
were unchanged after adjustment for creatinine excretion.
Most comparisons by ANCOVA indicated statistically signiﬁcant
differences in biomarkers of exposure to cigarette smoke HPHC and
excretion of mutagenic material in urine between the EHCSS-K6M
group and either the M4JM or Lark1M study groups on Day 5/6 (Ta-
ble 5), with lower levels in the EHCSS-K6M group.3.4. Serum Clara cell 16-kDa (CC16) concentrations
Serum CC16 concentrations were comparable in study groups at
baseline: 3.98 ± 1.01, 3.84 ± 1.38, 3.62 ± 1.30, and 3.90 ± 0.99 ng/ml
in the EHCSS-K6M, M4JM, Lark1M, and no-smoking groups, respec-
tively. At Day 6, serum CC16 concentrations were essentially un-
changed in the EHCSS-K6M, M4JM, and Lark1M groups
(3.90 ± 1.02, 3.87 ± 1.41, and 3.69 ± 1.47 ng/ml, respectively), and
slightly increased in the no-smoking group (4.12 ± 1.03 ng/ml).
None of the changes were signiﬁcant.
Table 4
Mean absolute biomarker levels and percentage change from Day -1/0 (baseline) to Day 5/6 per study group.
Smoke constituent biomarkera,b Study groupc
M4JM EHCSS-K6M Lark1M No-smoking
COHb17:00 (%)
§
Day 1/0 5.04 ± 1.57 5.30 ± 1.67 5.18 ± 2.12 5.07 ± 1.47
Day 5/6 5.10 ± 1.51 2.10 ± 0.29 4.48 ± 1.73 1.92 ± 0.72
Percentage change 1.96 ± 8.78% 57.0 ± 13.1%*** 11.7 ± 13.9*** 60.4 ± 9.4%***
COHbNcig10h (%)
Day 1/0 0.47 ± 0.12 0.52 ± 0.15 0.51 ± 0.17 0.51 ± 0.09
Day 5/6 0.49 ± 0.11 0.21 ± 0.06 0.44 ± 0.12 –
Percentage change 10.5 ± 20.2%* 52.9 ± 18.8%*** 13.6 ± 17.7%⁄⁄ –
DCOHb17:00-07:00 (%)
Day 1/0 1.56 ± 1.01 1.62 ± 0.92 1.50 ± 1.20 1.61 ± 0.85
Day 5/6 1.65 ± 0.89 0.06 ± 0.27 1.28 ± 0.97 0.10 ± 0.29
Absolute mean change 0.10 ± 0.42% 1.57 ± 1.23%*** 0.22 ± 0.62% 1.64 ± 0.68%***
DCOHb17:00-07:00/Ncig10h (%)
Day 1/0 0.14 ± 0.08 0.15 ± 0.09 0.13 ± 0.09 0.15 ± 0.06
Day 5/6 0.15 ± 0.07 0.01 ± 0.03 0.12 ± 0.07 –
Absolute mean change 0.02 ± 0.04%* 0.14 ± 0.09%*** 0.02 ± 0.06% –
NEq (mg/24 h)
Day 1/0 7.21 ± 3.91 7.17 ± 3.23 6.82 ± 3.96 6.91 ± 3.71
Day 5/6 7.23 ± 4.03 3.37 ± 1.61 5.27 ± 3.57 0.62 ± 0.87
Percentage change 0.9 ± 17.7% 49.2 ± 20.5%*** 20.4 ± 23.8%*** 91.9 ± 4.7%***
COT-P17:00 (ng/ml)
Day 1/0 149.8 ± 78.6 156.6 ± 67.0 152.0 ± 95.0 137.8 ± 83.6
Day 5/6 150.5 ± 81.1 79.4 ± 35.5 119.3 ± 75.7 11.1 ± 28.3
Percentage change 0.8 ± 18.6% 46.7 ± 17.5%*** 18.1 ± 24.5%*** 93.6 ± 9.0%***
MHBMA (lg/24 h)
Day 1/0 1.39 ± 1.22 2.21 ± 3.15 1.53 ± 1.27 2.51 ± 2.33
Day 5/6 1.45 ± 1.24 0.61 ± 1.06 1.31 ± 1.16 0.36 ± 0.58
Percentage change 5.6 ± 18.1% 18.9 ± 252.8%* 12.1 ± 32.3%* 78.9 ± 20.2%**
2-NA (ng/24 h)
Day 1/0 6.6 ± 8.3 8.6 ± 11.7 9.2 ± 12.7 7.5 ± 11.4
Day 5/6 4.6 ± 4.7 4.4 ± 1.1 5.8 ± 5.9 4.65 ± 1.57
Percentage change 15.4 ± 23.9 12.3 ± 34.9% 3.3 ± 34.0% 1.4 ± 41.0%
4-ABP (ng/24 h)
Day 1/0 9.5 ± 5.5 10.3 ± 6.4 9.7 ± 7.7 10.4 ± 5.7
Day 5/6 9.4 ± 5.3 4.4 ± 1.1 6.8 ± 4.5 4.7 ± 1.6
Percentage change 6.4 ± 38.2% 40.8 ± 35.9%*** 15.2 ± 33.5%** 40.1 ± 28.1%**
3-HPMA (mg/24 h)
Day -1/0 1.25 ± 0.67 1.27 ± 0.58 1.24 ± 0.64 1.37 ± 0.74
Day 5/6 1.19 ± 0.64 0.83 ± 0.32 1.02 ± 0.55 0.50 ± 0.20
Percentage change 2.5 ± 17.4% 27.9 ± 25.3%*** 16.8 ± 19.9%*** 59.2 ± 17.3%***
AAMA (lg/24 h)
Day 1/0 96.2 ± 75.3 137.6 ± 258.5 84.5 ± 32.9 91.6 ± 40.9
Day 5/6 83.7 ± 31.3 70.9 ± 55.2 71.1 ± 31.4 43.0 ± 13.8
Percentage change 0.3 ± 28.3% 27.2 ± 21.6% 14.0 ± 22.1%** 49.2 ± 15.0%***
S-PMA (lg/24 h)
Day 1/0 2.18 ± 1.59 2.83 ± 1.93 2.26 ± 1.77 3.75 ± 3.55
Day 5/6 2.26 ± 1.76 0.35 ± 0.13 1.88 ± 1.56 0.53 ± 1.03
Percentage change 1.6 ± 14.7% 83.4 ± 9.7%*** 11.9 ± 23.3%** 84.1 ± 11.9%⁄⁄⁄
3-HMPMA (mg/24 h)
Day 1/0 0.52 ± 0.21 0.51 ± 0.25 0.51 ± 0.25 0.56 ± 0.28
Day 5/6 0.53 ± 0.23 0.19 ± 0.08 0.41 ± 0.22 0.11 ± 0.06
Percentage change 6.2 ± 28.3% 58.6 ± 19.8%*** 16.6 ± 33.0%** 77.4 ± 11.0%***
Total NNAL (ng/24 h)
Day 1/0 202 ± 112 223 ± 147 193 ± 143 221 ± 154
Day 5/6 188 ± 104 95 ± 53 126 ± 88 80 ± 69
Percentage change 6.6 ± 14.1% 55.2 ± 8.6%*** 35.2 ± 11.3%*** 64.0 ± 7.5%***
Total 1-OHP (ng/24 h)
Day 1/0 150.4 ± 85.4 127.7 ± 67.9 129.6 ± 70.4 136.7 ± 50.6
Day 5/6 106.5 ± 53.6 38.4 ± 22.7 81.8 ± 42.0 37.4 ± 11.2
Percentage change 24.2 ± 19.4%⁄⁄ 67.7 ± 13.3%*** 34.8 ± 11.7%*** 70.5 ± 8.2%***
o-TOL (ng/24 h)
Day -1/0 68.2 ± 33.6 81.1 ± 89.4 64.9 ± 41.4 91.1 ± 95.8
Day 5/6 66.2 ± 32.2 33.6 ± 58.2 47.8 ± 31.0 33.8 ± 29.0
Percentage change 3.6 ± 31.1% 53.3 ± 26.6%*** 21.7 ± 25.1%⁄⁄⁄ 54.3 ± 23.4%**
(continued on next page)
A.R. Tricker et al. / Regulatory Toxicology and Pharmacology 64 (2012) S64–S73 S69
Table 4 (continued)
Smoke constituent biomarkera,b Study groupc
M4JM EHCSS-K6M Lark1M No-smoking
Mutagenicity (rev/24 h)d
Day 0 63032 ± 53459 79002 ± 57718 65866 ± 54847 85882 ± 73332
Day 6 64348 ± 54177 10356 ± 5746 51892 ± 43876 9913 ± 13211
Percentage change 6.24 ± 36.94% 80.99 ± 16.21%*** 1.12 ± 54.65% 86.89 ± 8.85%***
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 2-NA, 2-naphthylamine; 3-HPMA, 3-hydroxypropyl mercapturic acid; 3-HMPMA, 3-hydroxy-1-
methylpropyl mercapturic acid;4-ABP, 4-aminobiphenyl; AAMA, acrylamide mercapturic acid; COHb17:00, carboxyhemoglobin at 17:00; DCOHb17:00-07:00, difference in COHb
from 07:00 to 17:00; DCOHb17:00-07:00/Ncig10h, difference in COHb from 07:00 to 17:00 corrected for number of cigarettes smoked; COT-P17:00, plasma cotinine at 17:00;
MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NNAL, 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and
o-TOL, o-toluidine.
b On Day -1/0 (baseline) all groups smoked the M4JM cigarette. On Day 1 through Day 6 groups smoked their randomized study cigarette or stopped smoking.
c Groups abbreviated as: EHCSS-K6M, EHCSS series-K heater and EHCSS-K6 menthol cigarette (5 mg tar and 0.3 mg nicotine); M4JM,Marlboro Ultra Lights Menthol cigarette
(4 mg tar and 0.3 mg nicotine); Lark1M, Lark One menthol cigarette (1 mg tar and 0.1 mg nicotine); and No-smoking, smoking cessation group.
d Rev, revertants.
§ Primary objective.
* Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test: p < 0.05).
** Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test: p < 0.01).
*** Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test: p < 0.001).
Fig. 2. Percentage carboxyhemaglobin saturation (% COHb17:00) by group and study
day.
Table 5
Comparison between study cigarettes by ANCOVA (baseline-adjusted means on Day
5/6).
Smoke constituent
biomarkera
Comparisonb
EHCSS-K6M vs.
M4JM
EHCSS-K6M vs.
Lark1M
COHb17:00 (%)§ 3.16 ± 0.19*** 2.46 ± 0.18***
DCOHb17:00–07:00 (%) 1.65 ± 0.13*** 1.31 ± 0.13***
NEq (mg/24 h) 3.81 ± 0.41*** 2.18 ± 0.41***
COT-P17:00 (ng/ml) 76.16 ± 8.36*** 43.06 ± 8.34***
MHBMA (lg/24 h) 1.05 ± 0.28*** 0.87 ± 0.28**
2-NA (ng/24 h) 0.67 ± 1.01 1.38 ± 1.00
4-ABP (ng/24 h) 5.39 ± 0.74*** –2.70 ± 0.74***
3-HPMA (mg/24 h) 0.38 ± 0.06*** 0.21 ± 0.06⁄⁄
AAMA (lg/24 h) 21.70 ± 5.81*** 10.35 ± 5.83
S-PMA (lg/24 h) 2.30 ± 0.23*** 1.90 ± 0.23***
3-HMPMA (mg/24 h) 0.34 ± 0.04*** 0.23 ± 0.04***
Total NNAL (ng/24 h) 104.99 ± 10.38*** 48.48 ± 10.41***
Total 1-OHP (ng/24 h) 58.19 ± 7.24*** 40.34 ± 7.29***
o-TOL (ng/24 h) 40.56 ± 4.69*** 24.82 ± 4.71***
Mutagenicity (rev/24 h)d 53992 ± 19933*** 41536 ± 20117***
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 2-NA,
2-naphthylamine; 3-HPMA, 3-hydroxypropyl mercapturic acid; 3-HMPMA, 3-
hydroxy-1-methylpropyl mercapturic acid;4-ABP, 4-aminobiphenyl; AAMA, acryl-
amide mercapturic acid; COHb17:00, carboxyhemoglobin at 17:00; DCOHb17:00–07:00,
difference in COHb from 07:00 to 17:00; DCOHb17:00–07:00/Ncig10h, difference in
COHb from 07:00 to 17:00 corrected for number of cigarettes smoked; COT-P17:00,
plasma cotinine at 17:00; MHBMA, monohydroxybutenyl mercapturic acid; NEq,
nicotine equivalents; NNAL, 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol; S-
PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b Groups abbreviated as: EHCSS-K6M, EHCSS series-K heater and EHCSS-K6
menthol cigarette (5 mg tar and 0.3 mg nicotine); M4JM, Marlboro Ultra Lights
Menthol cigarette (4 mg tar and 0.3 mg nicotine); and Lark1M, Lark One menthol
cigarette (1 mg tar and 0.1 mg nicotine).
c Rev, revertants.
§ Primary objective.
⁄Least squares mean ± SE and Bonferoni-corrected p-value according to Dunnett:
p < 0.05.
** Least squares mean ± SE and Bonferoni-corrected p-value according to Dunnett:
p < 0.01.
*** Least squares mean ± SE and Bonferoni-corrected p-value according to Dunnett:
p < 0.001.
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Three subjects (3%) reported an AE after randomization (5 AE
episodes in total). None of the AEs were judged to be related to
the study cigarettes or study procedures. Reported AEs concerned
clinical symptoms (3 episodes of dysmenorrhea and one episode
of post-traumatic headache in the Lark1M and M4JM groups,
respectively) and mild laboratory disorders (1 episode of protein-
uria in the Lark1M group). All AEs resolved rapidly. Hematology
examinations showed no notable changes during the study. Urinal-
ysis revealed only sporadic cases of the presence of blood, ketones,
leukocyte esterase, nitrite, and proteins in urine. Slight increases in
mean BP and PR, and a decrease in body weight were noted in all
study groups, ECG recordings revealed no abnormality in any sub-
ject. There were no withdrawals due to an AE, and no occurrence of
a serious adverse event.
4. Discussion
The reported study of adult smokers in a controlled clinical
environment was conducted to evaluate changes in biomarkers
of exposure to selected HPHC in cigarette smoke, excretion ofmutagenic material in urine, and serum concentrations of a bio-
marker of lung epithelial injury (CC16), after switching from smok-
ing a conventional lit-end menthol cigarette (M4JM) to use an
EHCSS series-K heater and smoke an EHCSS series-K menthol ciga-
rette (EHCSS-K6M), or switching to smoke a lit-end menthol
cigarette of low tar and nicotine yield (Lark1M), or switching to
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minimize bias and variability, and selected biomarkers of exposure
to different gas–vapor and particulate phase cigarette smoke HPHC
were investigated (Table 1). Cigarette smoke HPHC were selected
based on the availability of validated methods of analysis for the
respective biomarkers of exposure.
The EHCSS-K6M cigarette was evaluated in Japan since Japanese
smokers are known to have a taste preference for mentholated
products compared to smokers in Western Europe (Ueda et al.,
2002; Giovino et al., 2004).
In a previous study (Tricker et al., 2012c), the non-mentholated
version of EHCSS-K6M was evaluated using a different experimen-
tal protocol to the one used in the current study. Since biomarkers
of exposure to nearly all HPHC, with the exception of total NNAL (a
biomarker of exposure to NNK), reached steady state excretion lev-
els after 3 to 4 days of randomization to the new test cigarette, the
protocol was shortened from 8 to 6 days of smoking the new test
cigarette. The average excretion of each biomarker of exposure
was calculated on Days 5/6 and compared to baseline on Days
1/0, while in the previous study comparisons at Day 8 were made
to baseline on Day 0. Due to the difference in protocol design, fur-
ther comparisons to the previous study (Tricker et al., 2012c) can-
not be made.
Controlled ‘switching’ was used to maintain a fairly constant
number of cigarettes smoked per day (Table 3) and to minimize
the effects of compensation on switching to smoke a cigarette of
different tar and nicotine yield (Scherer, 1999). Post hoc analysis
of NEqNcig excretion in the Lark1M group showed an average com-
pensation of 65% of the difference in nicotine yield1 at Day 5/6,
compared to baseline. Compensation in the EHCSS group could not
be calculated on a nicotine basis due to the identical mainstream
smoke nicotine yields of the M4JM and EHCSS-K6M cigarettes.
The observed reductions in the primary endpoint of the study,
exposure to CO determined as COHb17:00, at Day 5/6 (Table 4) are
consistent with other studies investigating reductions in exposure
to CO in smokers who switched to using previous generations of
the EHCSS heater and smoking EHCSS non-menthol cigarettes
(Buchhalter and Eissenberg, 2000; Buchhalter et al., 2001; Hughes
and Keely, 2004; Roethig et al., 2005, 2007) and the current third-
generation EHCSS series-K heater and series-K non-menthol ciga-
rettes (Frost-Pineda et al., 2008a,b; Martin Leroy et al., 2012; Trick-
er et al., 2012a,b,c). However, this is the only reported study to
have investigated the use of the EHCSS heater and EHCSS cigarettes
containing menthol.
Signiﬁcant reductions in exposure to nicotine (determined as
NEq and COT-P17:00) and NNK (determined as total NNAL) were ob-
served in the EHCSS-K6M, Lark1M, and no-smoking groups (all
p 6 0.001), but not in the M4JM group at Day 5/6, compared to
baseline. The reductions in exposure to nicotine determined as
NEq in urine were conﬁrmed by measurement of COT-P17:00. Bio-
markers of exposure to 1,3-butadiene, 4-aminobiphenyl, acrolein,
benzene, crotonaldehyde, pyrene, and o-toluidine were also signif-
icantly reduced (p 6 0.05) in the EHCSS-K6M group at Day 5/6,
compared to baseline, while reductions in exposure to 2-naphthyl-
amine and acrylamide were not signiﬁcant. Similar reductions
were also observed in the Lark1M group, although to a smaller
magnitude. Additionally, a small but signiﬁcant reduction
(p < 0.05) in exposure to acrylamide occurred in the Lark1M group
at Day 5/6, compared to baseline. In the no-smoking group, signif-
icant reductions (p 6 0.01) in exposure to 1,3-butadiene, 4-amino-
biphenyl, acrolein, acrylamide, benzene, crotonaldehyde, pyrene,
and o-toluidine, but not in exposure to 2-naphthylamine, were1 Compensation = 1  [%Change in NEq per cigarette/%Change of cigarette ISO
nicotine yield].observed at Day 5/6, compared to baseline. These observations are
similar to those observed in a previous study of slightly longer
duration in which the non-menthol version of the EHCSS-K6 ciga-
rette was assessed in a Japanese population (Tricker et al., 2012c).
A statistically signiﬁcant reduction (p < 0.001) in excretion of
mutagenic material in urine was observed in the EHCSS-K6M and
no-smoking groups at Day 6, compared to baseline (Table 4). Sim-
ilar observations of reduced excretion of mutagenic material in ur-
ine have also been reported in previous studies evaluating the use
of earlier generations of the EHCSS heater and non-menthol EHCSS
cigarettes (Roethig et al., 2005, 2007) and using the current EHCSS
series-K heater and series-K non-menthol cigarettes (Frost-Pineda
et al., 2008a; Tricker et al., 2012a,b,c). Unlike a previous study
(Tricker et al., 2012a), a signiﬁcant reduction in excretion of muta-
genic material in urine was not found after switching from a ciga-
rette of higher tar and nicotine yield to a low tar and nicotine yield
cigarette, i.e., switching from the M4JM cigarette to smoke the
Lark1M cigarette (1.12 ± 54.65%; p = not signiﬁcant) at Day 6,
compared to baseline. A signiﬁcant reduction in excretion of muta-
genic material in urine after switching from a high tar and nicotine
yield cigarette (M6J) to a low tar and nicotine yield cigarette
(Lark1J) was also not observed in another study (Tricker et al.,
2012c). However, post hoc analysis of data expressed as group
median values suggested that the excretion of mutagenic material
in the urine of the Lark1M group was reduced by 16.3%, while
excretion in the EHCSS-K6M (86.1% vs. 80.99%), M4JM (7.9% vs.
6.24%), and no-smoking (89.0% vs. 86.89%) groups was essentially
unchanged. The S. typhimurium YG1024 strain, an o-acetyltransfer-
ase-overproducing derivative of tester strain TA98, is sensitive to
the mutagenic activity of aromatic amino, hydroxylamino, and ni-
tro compounds present in urine (Einistö et al., 1990). Although the
mainstream cigarette smoke HPHC responsible for excretion of
mutagenic material in urine are unknown, 2-naphthylamine, 4-
aminobiphenyl, and o-toluidine were selected as representative
aromatic amino compounds present in cigarette smoke. In parallel
to the signiﬁcantly reduced excretion of mutagenic material in ur-
ine of the EHCSS-K6M and no-smoking groups (both p < 0.001), sig-
niﬁcant reductions in exposure to 4-aminobiphenyl and o-
toluidine (both p 6 0.01) were also observed, but no difference in
exposure to 2-naphthylamine was found at Day 5/6, compared to
baseline.
Comparisons of COHb17:00 and DCOHb17:00-07:00 at Day 5/6 be-
tween the EHCSS-K6M and M4JM or Lark1M groups showed statisti-
cally signiﬁcant between-group differences (p < 0.001), with lower
values for the EHCSS-K6M group (Table 5). Similarly, comparisons
of biomarkers of exposure to 4-aminobiphenyl, benzene, crotonal-
dehyde, nicotine (determined as both COT-P17:00 and NEq), NNK,
pyrene, o-toluidine, and excretion of mutagenic material in urine
at Day 5/6 between the EHCSS-K6M and M4JM or Lark1M groups
showed statistically signiﬁcant between-group differences
(p < 0.001), with lower values for the EHCSS-K6M group. Compari-
sons of biomarkers of exposure to 1,3-butadiene and acrolein at
Day 5/6 showed statistically signiﬁcant between-group differences
between the EHCSS-K6M and M4JM groups (p < 0.001) and between
the EHCSS-K6M and Lark1M groups (p < 0.01), with lower values for
the EHCSS-K6M group. While comparisons of a biomarker of expo-
sure to acrylamide at Day 5/6 showed a statistically signiﬁcantly
lower level in the EHCSS-K6M group compared to in the M4JM
group (p < 0.01), the differences between the EHCSS-K6M and
Lark1M groups were not statistically signiﬁcant. For 2-naphthyl-
amine, no statistically signiﬁcant inter-group differences at Day
5/6 were found between the EHCSS-K6M group and the M4JM and
Lark1M groups.
Decreased serum concentrations of CC16 protein, an investiga-
tional biomarker of early peripheral tobacco smoke-induced lung
epithelial injury (Robin et al., 2002), have been observed in
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et al., 2002; Shijubo et al., 1997, 1998; Van Miert et al., 2011).
Indeed, decreased levels of serum CC16 can already be detected
in young adults with a median of 3.8 pack years of smoking history
(dell’Omo et al., 2000). It is thought that the reduced levels of
serum CC16 in smokers most probably reﬂect a progressive loss
of CC16-positive cells in terminal airways (Shijubo et al., 1997).
In this study, serum CC16 concentrations were not signiﬁcantly
changed in any group at Day 6, compared to baseline. Although a
slight increase in the serum concentration was observed in the
no-smoking group at Day 6, compared to baseline, this may have
been a chance observation or may indicate that the study duration
was too short to assess changes in this biomarker.
It should be noted that there are some potential limitations to
the present study design, in particular, the short study duration.
However, statistically signiﬁcant changes in biomarkers of expo-
sure to several selected cigarette smoke HPHC were observed (Ta-
ble 4). The selected biomarkers of exposure were chosen to
represent different chemical classes present in mainstream tobac-
co smoke. Although exposure to 4-aminobiphenyl and, to a lesser
extent, 2-naphthylamine was reduced in the EHCSS-K6M, Lark1M,
and no-smoking groups, many of the analytical measurements
were below the respective LLOQ values, even prior to randomiza-
tion. In addition, some doubt exists as to the speciﬁcity of biomark-
ers used to determine exposure to acrolein (Stevens and Maier,
2008) and crotonaldehyde (Hecht et al., 2001). Despite these limi-
tations, the combined data suggest that reduced exposure to se-
lected cigarette smoke HPHC and excretion of mutagenic
material in urine of the EHCSS-K6M group occurred at Day 5/6,
compared to the M4JM group. The results of this study cannot be
extrapolated to predict the long-term effects of switching to use
the EHCSS series-K heater and smoking EHCSS menthol cigarettes
under real-life conditions.
In summary, this study shows reductions in the mean values of
individual biomarkers of exposure to selected cigarette smoke
HPHC from baseline to Day 5/6 in smokers of the M4JM cigarette
who switch to use the EHCSS series-K heater and smoke the
EHCSS-K6M menthol cigarette (12.3 ± 34.9% to 83.4 ± 9.7%). In
smokers who switched to smoke the Lark1M menthol cigarette, a
conventional lit-end cigarette representative of the low-tar men-
thol cigarette market, reductions in exposure to individual ciga-
rette smoke HPHC were smaller (3.3 ± 34.0% to 35.2 ± 11.3%).
The largest reductions in individual cigarette smoke HPHC oc-
curred in smokers who switched to no-smoking (1.4 ± 41.0% to
93.6 ± 9.0%). Reductions in the mean excretion of mutagenic
material in urine occurred in the EHCSS-K6M (80.99 ± 16.21%)
and no-smoking (86.89 ± 8.85%) groups, but not in the M4JM
(6.24 ± 36.94%) and Lark1M (1.12 ± 54.65%) groups. Changes in
serum concentrations of Clara cell 16-kDa protein could not be
meaningfully interpreted.Conﬂict of Interest statement
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